- Source Facts: Kiwoom Securities Research Center (Based on the report published on July 7, 2026)
- Investment Opinion & Target Price: BUY Maintained / Target Price Maintained at KRW 380,000
- Key Momentum: Robust global export trends in toxin and filler lines coupled with a faster-than-expected transition into the U.S. direct sales operational model.
๐ 1. [Valuation Metrics and Investment Indicator Analysis]
Independent Investment Indicator Summary (Based on 2026 Full-Year Estimates)
- Valuation Architecture: The target price of KRW 380,000 was sustained by applying a target P/E multiple of 25x to the forward 4-quarter EPS forecast of KRW 15,539. The current 2026F P/E ratio hovers at 16.5x, trading significantly below its historical post-listing average of 24.5x.
- Balance Sheet & Multiple Parameters: Based on 2026 forecasts, BPS is estimated at KRW 92,978, with the PBR multiple recorded at 2.74x and EV/EBITDA at 9.7x.
- Profitability & Liquidity Stability:
- 2026F Return on Equity (ROE) is projected to reach 18.2% alongside an operating profit margin of 41.6%, showing resilient operational efficiency.
- The net debt ratio remains highly favorable at -59.1%, underscoring solid net cash reserves and balance sheet strength.
Annual Earnings Trajectory Trends
- Revenue: KRW 373.0 billion in 2024 $\rightarrow$ KRW 425.1 billion in 2025 $\rightarrow$ KRW 544.7 billion in 2026F (YoY +28.1%)
- Operating Profit: KRW 166.2 billion in 2024 $\rightarrow$ KRW 200.9 billion in 2025 $\rightarrow$ KRW 226.4 billion in 2026F (YoY +12.7%)
- Net Profit (Controlling Interest): Transitioning from KRW 140.9 billion in 2025 to KRW 190.6 billion in 2026F, and forecasted to further advance to KRW 233.4 billion by 2027F.
๐ 2. [Market Opportunity (TAM) and Detailed Earnings Estimates]
Quarterly Dynamics and Core Segment Margin Profiles
- Q2 Consolidated Preview: For 2Q26, consolidated revenue is forecast at KRW 133.0 billion (+20.6% YoY) and operating profit is projected at KRW 52.9 billion (-6.6% YoY, OPM 39.8%), surpassing the consensus benchmarks by 5.1% and 3.7% respectively.
- Botulinum Toxin Segment: 2Q26 toxin revenue is modeled at KRW 73.7 billion, with international shipments executing strongly at KRW 53.5 billion (Asia-Pacific KRW 27.3 billion, Americas KRW 20.0 billion, Europe & Others KRW 6.2 billion). Domestic toxin lines (2Q26 KRW 20.2 billion) have averted structural contraction through volume discount frameworks enacted since 2H25.
- Dermal Filler Segment: 2Q26 revenue is estimated at KRW 36.8 billion, split between international volumes of KRW 30.5 billion and domestic demand of KRW 6.3 billion.
- Cost Friction and Seasonality Matrix: While the Q2 gross margin reflects transient batch overheads at Plant 3 (averaging 77.3%), normalizations above 78% are expected in 2H26 as operating costs shift into a back-loaded cadence due to strategic upfront commercializations and U.S. launch allocations.
Global Market Access and Addressable Horizon (TAM)
- U.S. Commercialization Acceleration: Following the conclusion of validation testing, direct sales distributions are set to go live early in 2H26. Subsidiary procurement protocols reveal an aggregated KRW 94,975 thousand USD commitment over the next three years, securing predictable volume flows into the North American infrastructure.
- Total Addressable Market: The company’s global addressable field (TAM) across botulinum and regenerative aesthetic lines is mapped at approximately KRW 14 trillion for 2026F. Infiltration plans rely on aggressive portfolio bundle integrations, in-licensing deals, and targeted corporate actions to exploit growth in key geographies such as the United States and Brazil.
๐ Editor Comment
Hugelโs market valuation has consolidated following macro-driven pullbacks that adjusted for prior litigation clearances and registration catalysts. However, the fundamental structure of its international revenue matrix continues to strengthen. As revealed in the second-quarter forecast, the stabilization of the domestic retail footprint via volume incentives provides an effective baseline, while the primary export vectors throughout the Asia-Pacific and Americas maintain robust traction. Crucially, the looming launch of its independent direct-to-market commercial channel in the United Statesโbacked by verified logistics systems and strategic local hiringโshifts the narrative from cost-drag anxieties to long-term margin ownership. Although front-loaded launch programs and manufacturing provisions may temporarily pinch margins early in the year, the combination of scalable plant infrastructure and localized capture capability suggests the company is well positioned for compounding terminal cash flows.
๐ข Disclaimer and Source
Source
This content has been newly structured and written based on financial facts and numerical data from officially disclosed securities analysis reports.
Investment Risk Notice
This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific financial instruments. All investment decisions and financial liabilities rest entirely with the individual investor.
Contact
Compliance & Copyright Inquiries
ksb220805@gmail.com
๐ฅ Bulls vs Bears, drop your analysis in the comments!
